Alemtuzumab: all 222 studies that test it

Page 1 of 3. Open to participants first (13), then studies with results posted, then the rest; newest registration first within each.

• Haploidentical Donor Hematopoietic Cell Transplant for Sickle Cell DiseaseRecruitingNCT07616154Phase 2
• Partial Stem Cell Transplant for Sickle Cell Disease From Matched DonorsRecruitingNCT07599176Phase 1/2
• Base Editing Hematopoietic Stem Cell and T Cell Gene Therapy for CD40L-HyperIgM Syndrome: Single Patient StudyRecruitingNCT06959771Phase 1/2
• Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous DiseaseRecruitingNCT06325709Phase 1/2
• Intestinal & Multivisceral Transplantation for Unresectable Mucinous Carcinoma Peritonei (TRANSCAPE)Not yet recruitingNCT06084780Phase 2
• Precision Alemtuzumab Dosing for Allogeneic Hematopoietic Cell TransplantationRecruitingNCT05501756Phase 2
• T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other AnemiasRecruitingNCT03653338Phase 1/2
• Autologous Stem Cell Transplantation in Patients With Systemic SclerosisRecruitingNCT03630211Phase 2
• Minimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell DiseaseRecruitingNCT03587272Phase 2
• Alpha/Beta TCD HCT in Patients With Inherited BMF DisordersRecruitingNCT03579875Phase 2
• Lung and Bone Marrow Transplantation for Lung and Bone Marrow FailureRecruitingNCT03500731Phase 1/2
• Nonmyeloablative Stem Cell Transplant in Children With Sickle Cell Disease and a Major ABO-Incompatible Matched Sibling DonorRecruitingNCT03214354Phase 2
• Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCTRecruitingNCT01962415Phase 2
• A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMTTerminatedNCT03368664Phase 3Results posted
• Sequential Natalizumab - Alemtuzumab Therapy in Patients With Relapsing Forms of Multiple SclerosisCompletedNCT03135249Phase 4Results posted
• Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell DiseaseActive, not recruitingNCT03077542Phase 1/2Results posted
• Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503)CompletedNCT02766465Phase 2Results posted
• Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)CompletedNCT02689453Phase 1Results posted
• Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant FailureActive, not recruitingNCT02105766Phase 2Results posted
• SCD-Haplo: Phase II Study of HLA-Haploidentical SCT for Aggressive SCDTerminatedNCT02013375Phase 2Results posted
• Stem Cell Transplantation for Sickle Cell AnemiaCompletedNCT01877837Phase 3Results posted
• Belatacept Early Steroid Withdrawal TrialCompletedNCT01729494Phase 4Results posted
• Reduced-Intensity Hematopoietic Stem Cell Transplant for High Risk Lysosomal and Peroxisomal DisordersCompletedNCT01626092Not applicableResults posted
• Ofatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzumab in 17p CLLTerminatedNCT01465334Phase 2Results posted
• Optimization of NULOJIX® Usage As A Means of Avoiding CNI and Steroids in Renal TransplantationTerminatedNCT01436305Phase 2Results posted
• Alemtuzumab on Surrogate Markers of Disease Activity and Repair Using Advanced MRI Measures in Subjects With Relapsing Remitting Multiple SclerosisCompletedNCT01395316Phase 4Results posted
• Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic LeukemiaActive, not recruitingNCT01361711Phase 2Results posted
• Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic LeukemiaCompletedNCT01269385Phase 1/2Results posted
• Immunophenotyping of Peripheral T Cells After T Cell Depletion With AlemtuzumabTerminatedNCT01213329Phase 4Results posted
• Safety and Efficacy of Alemtuzumab in Pediatric Intestinal TransplantationCompletedNCT01208337Phase 2Results posted
• Alemtuzumab in Myelodysplastic Syndrome (MDS), Aplastic Anemia, and T-Cell Large Granular Lymphocytic Leukemia (T-GL)TerminatedNCT01191749Phase 2Results posted
• Randomized Trial of 2 Antibody Induction Steroid Avoidance ProtocolsCompletedNCT01172418Phase 4Results posted
• Campath, Calcineurin Inhibitor Reduction and Chronic Allograft NephropathyCompletedNCT01120028Phase 2/3Results posted
• Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)CompletedNCT01082939Phase 2Results posted
• Allogeneic Bone Marrow Transplant for Inherited Metabolic DisordersCompletedNCT01043640Phase 2Results posted
• Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin LymphomasCompletedNCT01030900Phase 2Results posted
• Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic LeukemiaTerminatedNCT01013961Phase 2Results posted
• Alemtuzumab and Clofarabine for Relapsed or Refractory Acute Lymphoblastic LeukemiaTerminatedNCT00983528Phase 1/2Results posted
• Everolimus and Alemtuzumab in Treating Patients With Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT00935792Phase 1/2Results posted
• An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of AlemtuzumabCompletedNCT00930553Phase 3Results posted
• A Phase II Trial of Alemtuzumab and Rituximab in Patients With Previously Untreated CLLCompletedNCT00858117Phase 2Results posted
• Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic CancerTerminatedNCT00818961Phase 2Results posted
• Double Cord Blood Transplant for Patients With Malignant and Non-malignant DisordersTerminatedNCT00801931Phase 1/2Results posted
• Alemtuzumab + Rituximab Consolidation in CLLTerminatedNCT00771602Phase 2Results posted
• Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell TransplantationTerminatedNCT00698685Phase 2Results posted
• Reduced Intensity Transplant in Medically Refractory Systemic Lupus Erythematosus (SLE) and Systemic Sclerosis (SSc)TerminatedNCT00684255Phase 1Results posted
• T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic MalignanciesCompletedNCT00683046Phase 2Results posted
• Pentostatin, Alemtuzumab, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT00669318Phase 2Results posted
• Hematopoietic Stem Cell Transplantation (HCT) for Inborn Errors of MetabolismTerminatedNCT00668564Phase 2Results posted
• Reduced Intensity AlloTransplant For OsteopetrosisTerminatedNCT00638820Phase 2Results posted
• Reduced Intensity Hematopoietic Cell Transplantation for Patients With Resistant Langerhans Cell HistiocytosisTerminatedNCT00618540Phase 2Results posted
• Antibody Conditioning Regimen For Allogeneic Donor Stem Cell Transplantation Of Patients With Fanconi AnemiaTerminatedNCT00590460Phase 1/2Results posted
• Campath Maintenance in Chronic Lymphocytic LeukemiaTerminatedNCT00587847Not applicableResults posted
• Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Malignant Hematological DiseasesCompletedNCT00582894Not applicableResults posted
• Allogeneic SCT Of Pts With SCID And Other Primary Immunodeficiency DisordersTerminatedNCT00579137Phase 1/2Results posted
• Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB)TerminatedNCT00579111Phase 1/2Results posted
• Allogeneic Stem Cell Transplant for Patients With Severe Aplastic AnemiaTerminatedNCT00578903Phase 2Results posted
• Matched Unrelated or Non-Genotype Identical Related Donor Transplantation For Chronic Granulomatous DiseaseCompletedNCT00578643Phase 2Results posted
• T-Reg Cell Kinetics, Stem Cell Transplant, REGALETerminatedNCT00578539Not applicableResults posted
• Bone Marrow Transplantation, Hemoglobinopathies, SCALLOPTerminatedNCT00578344Not applicableResults posted
• Allogeneic Stem Cell Transplantation, Severe Homzygous 0/+Thalassemia or Sever Variants of Beta 0/+ Thalassemia, THALLOTerminatedNCT00578292Not applicableResults posted
• Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological MalignanciesCompletedNCT00566696Phase 2Results posted
• Rituximab, Alemtuzumab, and GM-CSF As First-Line Therapy in Treating Patients With Early-Stage Chronic Lymphocytic LeukemiaCompletedNCT00562328Phase 2Results posted
• Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With Hematologic CancerTerminatedNCT00555048Phase 1/2Results posted
• Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by a Donor Stem Cell Transplant in Treating Patients With Immunodeficiency or Other Nonmalignant Inherited DisordersCompletedNCT00553098Phase 2Results posted
• Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study TwoCompletedNCT00548405Phase 3Results posted
• Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid MalignanciesCompletedNCT00536978Phase 2Results posted
• Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study OneCompletedNCT00530348Phase 3Results posted
• CFAR Study in Patients With Chronic Lymphocytic LeukemiaCompletedNCT00525603Phase 2Results posted
• Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune SystemCompletedNCT00520130Phase 1/2Results posted
• Autologous and Allogenic Transplantation With Campath-1H for T-Cell LymphomaTerminatedNCT00505921Phase 2Results posted
• Campath in Chronic GVHDCompletedNCT00495755Phase 1Results posted
• Stem Cell Transplant (SCT) for Dyskeratosis Congenita or SAACompletedNCT00455312Phase 2/3Results posted
• Alemtuzumab and Pentostatin In T-cell NeoplasmsTerminatedNCT00453193Phase 2Results posted
• Alemtuzumab and Rituximab in Treating Patients With High-Risk, Early-Stage Chronic Lymphocytic LeukemiaCompletedNCT00436904Phase 2Results posted
• Donor Stem Cell Transplantation for Congenital ImmunodeficienciesCompletedNCT00426517Early Phase 1Results posted
• Flu,Alemtuzumab,and TBI Followed By Donor Stem Cell Chronic Phase CMLTerminatedNCT00416884Phase 2Results posted
• T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell GraftsCompletedNCT00368355Phase 2Results posted
• "A Pilot Study to Determine the Safety of Campath-1H (Anti-CD52) Therapy in Primary Renal Allograft Transplantation"CompletedNCT00365846Phase 2Results posted
• Alemtuzumab (Campath) to Treat T-Large Granular Lymphocyte LeukemiaCompletedNCT00345345Phase 2Results posted
• Study of Alemtuzumab Versus Anti-thymocyte Globulin to Help Prevent Rejection in Kidney and Pancreas TransplantationCompletedNCT00331162Phase 4Results posted
• Subcutaneous Alemtuzumab (CAMPATH®, MabCampath®) in Relapsed/Refractory B-Cell Chronic Lymphocytic LeukemiaCompletedNCT00328198Phase 2Results posted
• Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic DisordersCompletedNCT00301834Phase 2Results posted
• Rheumatoid Arthritis:Tolerance Induction by Mixed ChimerismTerminatedNCT00282412Phase 1Results posted
• Hematopoietic Stem Cell Support in VasculitisTerminatedNCT00278512Phase 1Results posted
• Combination Chemotherapy and Alemtuzumab in Treating Patients With Relapsed or Refractory Acute Lymphoblastic LeukemiaTerminatedNCT00262925Phase 2Results posted
• Three Immunosuppressive Treatment Regimens for Severe Aplastic AnemiaCompletedNCT00260689Phase 2Results posted
• Safety in Immunomodulatory Functions of Alemtuzumab (Campath) in Pediatric Kidney Transplantation RecipientsCompletedNCT00240994Phase 2Results posted
• Phase 2 Fludarabine, Cytoxan and FCCAM <Alemtuzumab> in Untreated B-Cell Chronic Lymphocytic LeukemiaCompletedNCT00230282Phase 2Results posted
• A Pilot Study of Alemtuzumab (Campath[R]) in Patients With Myelodysplastic SyndromeCompletedNCT00217594Phase 2Results posted
• Alemtuzumab/Fludarabine for Relapsed/Refractory B-cell Chronic Lymphocytic Leukemia (B-CLL)CompletedNCT00206726Phase 2Results posted
• Alemtuzumab to Treat Severe Aplastic AnemiaCompletedNCT00195624Phase 2Results posted
• Stem Cell Transplant for Immunologic or Histiocytic DisordersCompletedNCT00176865Phase 2Results posted
• Stem Cell Transplant for HemoglobinopathyCompletedNCT00176852Phase 2/3Results posted
• Campath-1H Induction to Allow Steroid Free Immunosuppression in Pediatric Renal TransplantationTerminatedNCT00167661Phase 1/2Results posted
• Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic CancerCompletedNCT00118352Phase 2Results posted
• Safety/Efficacy of Induction Agents With Tacrolimus, MMF, and Rapid Steroid Withdrawal in Renal Transplant RecipientsCompletedNCT00113269Phase 4Results posted
• Immune System Suppression With Alemtuzumab and Tacrolimus in Liver Transplantation PatientsCompletedNCT00105235Phase 2Results posted
• Fludarabine, Rituximab, and Alemtuzumab in Treating Patients With Chronic Lymphocytic LeukemiaCompletedNCT00098670Phase 2Results posted
• Pentostatin, Cyclophosphamide, and Rituximab Followed By Campath-1H in Patients With Relapsed or Refractory B-Cell CLLCompletedNCT00074282Phase 2Results posted

← Alemtuzumab overview